NJ A1439 | 2024-2025 | Regular Session

Note: Carry Over of previous A553
Note: Carry Over of previous S301

Status

Spectrum: Partisan Bill (Democrat 8-0)
Status: Introduced on January 9 2024 - 25% progression
Action: 2024-01-09 - Introduced, Referred to Assembly Financial Institutions and Insurance Committee
Pending: Assembly Financial Institutions and Insurance Committee
Text: Latest bill text (Introduced) [HTML]

Summary

Provides that purchase of insulin is not subject to deductible; requires health insurers to limit copayments and coinsurance for insulin; requires insulin manufacturers to submit report to Commissioner of Banking and Insurance.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Provides that purchase of insulin is not subject to deductible; requires health insurers to limit copayments and coinsurance for insulin; requires insulin manufacturers to submit report to Commissioner of Banking and Insurance.

Sponsors


History

DateChamberAction
2024-01-09AssemblyIntroduced, Referred to Assembly Financial Institutions and Insurance Committee

Same As/Similar To

A553 (Carry Over) 2022-01-11 - Introduced, Referred to Assembly Financial Institutions and Insurance Committee
S301 (Carry Over) 2022-01-11 - Introduced in the Senate, Referred to Senate Commerce Committee

Subjects


New Jersey State Sources


Bill Comments

feedback